Aperio Group’s Adamas Pharmaceuticals ADMS Stock Holding History

Aperio Group’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-107	Closed	-$1K	–	2921
2019 Q2	$1K	Buy	+107	New	+$616	﹤0.01%	3002

Other funds holding ADMS

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aperio Group's ADMS Position: Q3 2019 in Review

Aperio Group sold out of Adamas Pharmaceuticals (ADMS) in Q3 2019, closing a stake of 107 shares — an estimated $1K sold.

Aperio Group first reported a position in ADMS in Q2 2019 and held it in 1 quarter. The position peaked at $1K in Q2 2019. 87 funds tracked by Wall St. Rank hold ADMS as of Q3 2019.

Aperio Group reported no remaining Adamas Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Aperio Group sold 107 Adamas Pharmaceuticals shares in Q3 2019, an estimated $1K.
Aperio Group first reported a position in Adamas Pharmaceuticals in Q2 2019 and held it in 1 quarter.
Aperio Group's Adamas Pharmaceuticals position peaked at $1K in Q2 2019.
87 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.